
CureVac N.V. CVAC
Quarterly report 2022-Q2
added 08-18-2022
CureVac N.V. Total Assets 2011-2026 | CVAC
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets CureVac N.V.
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 1.16 B | 1.51 B | 131 M | 126 M | - | - | - | - | - | - | - |
All numbers in EUR currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.51 B | 126 M | 731 M |
Quarterly Total Assets CureVac N.V.
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 926 M | 1.03 B | 1.16 B | 1.66 B | - | - | 1.51 B | - | - | - | 131 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in EUR currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.66 B | 131 M | 1.07 B |
Total Assets of other stocks in the Biotechnology industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
2.03 B | - | 2.43 % | $ 254 M | ||
|
Alector
ALEC
|
293 M | $ 2.19 | -9.77 % | $ 226 M | ||
|
Acer Therapeutics
ACER
|
11.6 M | - | 2.71 % | $ 14 M | ||
|
I-Mab
IMAB
|
6.33 B | - | - | $ 866 M | ||
|
Cabaletta Bio
CABA
|
254 M | $ 3.34 | 0.45 % | $ 3.9 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
18.1 B | - | - | $ 40.3 B | ||
|
AgeX Therapeutics
AGE
|
12 M | - | -10.17 % | $ 12.2 K | ||
|
Biophytis SA
BPTS
|
12 M | - | -13.47 % | $ 169 M | ||
|
Aeglea BioTherapeutics
AGLE
|
778 M | - | - | $ 1.01 B | ||
|
Codexis
CDXS
|
149 M | $ 1.02 | 1.49 % | $ 74.9 M | ||
|
AbCellera Biologics
ABCL
|
1.36 B | $ 3.74 | 3.6 % | $ 1.12 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
66.7 M | - | - | $ 26.5 M | ||
|
Cerus Corporation
CERS
|
201 M | $ 2.6 | 1.37 % | $ 480 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
15.2 M | - | -1.52 % | $ 24.7 M | ||
|
Midatech Pharma plc
MTP
|
14.8 M | - | -18.52 % | $ 27.3 M | ||
|
Cellectis S.A.
CLLS
|
384 M | $ 3.87 | -0.39 % | $ 116 M | ||
|
ARCA biopharma
ABIO
|
396 M | - | 1052.0 % | $ 415 M | ||
|
Acorda Therapeutics
ACOR
|
109 M | - | -24.86 % | $ 820 K | ||
|
Acasti Pharma
ACST
|
72 M | - | 4.01 % | $ 150 M | ||
|
CNS Pharmaceuticals
CNSP
|
8.7 M | $ 3.23 | 2.22 % | $ 1.23 M | ||
|
Adverum Biotechnologies
ADVM
|
180 M | - | - | $ 86.2 M | ||
|
Институт стволовых клеток человека
ISKJ
|
1.51 B | - | - | - | ||
|
AIkido Pharma
AIKI
|
47.1 M | - | 1.93 % | $ 17.4 M | ||
|
Collegium Pharmaceutical
COLL
|
1.66 B | $ 41.75 | 0.19 % | $ 1.32 B | ||
|
Akero Therapeutics
AKRO
|
826 M | - | - | $ 3.67 B | ||
|
Akouos
AKUS
|
279 M | - | 0.23 % | $ 488 M | ||
|
Albireo Pharma
ALBO
|
302 M | - | -0.23 % | $ 916 M | ||
|
Corcept Therapeutics Incorporated
CORT
|
837 M | $ 36.14 | 1.23 % | $ 3.75 B | ||
|
Allena Pharmaceuticals
ALNA
|
34.8 M | - | 3.16 % | $ 1.9 M | ||
|
Amarin Corporation plc
AMRN
|
832 M | $ 13.98 | 1.27 % | $ 5.7 B | ||
|
Aileron Therapeutics
ALRN
|
62.2 M | - | 10.36 % | $ 9.8 M | ||
|
AlloVir
ALVR
|
119 M | - | 4.14 % | $ 49.1 M | ||
|
Catalyst Pharmaceuticals
CPRX
|
1.1 B | $ 23.77 | 2.99 % | $ 2.91 B | ||
|
Alpine Immune Sciences
ALPN
|
287 M | - | - | $ 2.17 B | ||
|
Corbus Pharmaceuticals Holdings
CRBP
|
28.3 M | $ 8.41 | -1.87 % | $ 36.4 M | ||
|
Cardiff Oncology
CRDF
|
61.9 M | $ 1.94 | 0.01 % | $ 130 M | ||
|
Curis
CRIS
|
41.3 M | $ 1.1 | -3.51 % | $ 6.94 M | ||
|
Aeterna Zentaris
AEZS
|
35.1 M | - | 5.93 % | $ 314 M | ||
|
CorMedix
CRMD
|
82.1 M | $ 7.16 | 0.42 % | $ 364 M | ||
|
Ampio Pharmaceuticals
AMPE
|
5.74 M | - | -11.43 % | $ 502 K | ||
|
Applied Molecular Transport
AMTI
|
107 M | - | - | $ 10.1 M | ||
|
Champions Oncology
CSBR
|
32.3 M | $ 6.14 | 3.89 % | $ 83.9 M | ||
|
Aravive
ARAV
|
62.2 M | - | -13.39 % | $ 1.45 M | ||
|
Aptose Biosciences
APTO
|
10.1 M | - | -45.71 % | $ 1.2 M | ||
|
Aptinyx
APTX
|
66.7 M | - | -39.0 % | $ 4.57 M | ||
|
Citius Pharmaceuticals
CTXR
|
117 M | $ 0.72 | -2.34 % | $ 4.84 M | ||
|
Athira Pharma
ATHA
|
58.8 M | - | - | $ 269 M | ||
|
Aridis Pharmaceuticals
ARDS
|
14.7 M | - | 17.91 % | $ 11.1 M | ||
|
Altimmune
ALT
|
139 M | $ 4.21 | -2.32 % | $ 299 M | ||
|
CEL-SCI Corporation
CVM
|
27 M | $ 3.88 | -8.92 % | $ 247 M |